John Lizcano
Biographic Data
| ID | 7990321 |
|---|---|
| NAME | John Lizcano |
| GIVEN NAMES | John |
| FAMILY NAME | Lizcano |
| SIGNATURE | LIZCANO J |
| AFFILIATIONS | Yale University |
| ORCID | 0000-0003-4470-2189 |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya
Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population. U…
Impact of scaling up harm reduction interventions on injecting risk behaviours, ART outcomes and HIV incidence among people who inject drugs in Kenya
This study provides strong evidence for the benefits of NSP and OAT on varied HIV outcomes among PWID in Africa
Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings
People who inject drugs (PWID) living with Hepatitis C (HCV) in low- and middle-income countries face substantial barriers to HCV care. We sought to gain healthcare providers' perspectives on challenges and best practices for HCV care provision among PWID in Kenya. We conducted three focus group discussions (FGD) with 23 healthcare providers working with PWID living with HCV in Nairobi and Mombasa. Transcribed interviews were analysed thematicall…
An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We measured the cost-effectiveness of a pilot HCV screening and treatment intervention using directly observed therapy among PWID attending harm reduction services in Nairobi, Kenya. DESIGN: We utilized an existing model of HIV and HCV transmission among current and forme…
Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya
Despite disproportionately high rates of Hepatitis C (HCV) among people who inject drugs (PWID) in low- and middle-income countries (LMICs), understanding of HCV-related knowledge, attitudes and perceived risk behaviours among this population remains limited. We aimed to elucidate knowledge, attitudes and experiences that could minimise transmission risk and maximise HCV treatment engagement among PWID in Kenya following the integration of HCV sc…
No prominent works on this page.
An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya
BACKGROUND AND AIMS: Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We measured the cost-effectiveness of a pilot HCV screening and treatment intervention using directly observed therapy among PWID attending harm reduction services in Nairobi, Kenya. DESIGN: We utilized an existing model of HIV and HCV transmission among current and forme…
Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya
Despite disproportionately high rates of Hepatitis C (HCV) among people who inject drugs (PWID) in low- and middle-income countries (LMICs), understanding of HCV-related knowledge, attitudes and perceived risk behaviours among this population remains limited. We aimed to elucidate knowledge, attitudes and experiences that could minimise transmission risk and maximise HCV treatment engagement among PWID in Kenya following the integration of HCV sc…
Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings
People who inject drugs (PWID) living with Hepatitis C (HCV) in low- and middle-income countries face substantial barriers to HCV care. We sought to gain healthcare providers' perspectives on challenges and best practices for HCV care provision among PWID in Kenya. We conducted three focus group discussions (FGD) with 23 healthcare providers working with PWID living with HCV in Nairobi and Mombasa. Transcribed interviews were analysed thematicall…
Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya
Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population. U…
Impact of scaling up harm reduction interventions on injecting risk behaviours, ART outcomes and HIV incidence among people who inject drugs in Kenya
This study provides strong evidence for the benefits of NSP and OAT on varied HIV outcomes among PWID in Africa
HIV, Drug Use, Sexual Risk (6 works) · Medicine (6 works) · Environmental health (5 works) · Hepatitis B Virus Studies (5 works) · Hepatitis C (5 works) · Hepatitis C virus research (5 works) · Family medicine (4 works) · Virology (4 works) · Population (3 works) · Harm reduction (2 works)